Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 20/20 | 0.70 |
| ▸ | TTK | P33981 | 2/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948473 | 0.87 | PRKDC (0.69) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL23948202 | 0.86 | PRKDC (0.84) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL23948537 | 0.85 | PRKDC (0.70) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL29502093 | 0.85 | PRKDC (0.71) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL23948123 | 0.85 | PRKDC (0.71) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL30030953 | 0.85 | PRKDC (0.71) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL30029442 | 0.84 | PRKDC (0.70) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL30031101 | 0.84 | PRKDC (0.73) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL23948607 | 0.84 | PRKDC (0.70) | PRKDCTTKKCNH2PIK3CDCSF1R | |
| SCHEMBL29501860 | 0.84 | PRKDC (0.75) | PRKDCTTKKCNH2PIK3CDCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022177302-A1 | PYRIMIDINE-FUSED RING COMPOUND WITH DNA-PK INHIBITION ACTIVITY AND USE THEREOF | 보령제약 주식회사 | 2022-08-25 | — | — | WO | claimed |
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022177302-A1 | PYRIMIDINE-FUSED RING COMPOUND WITH DNA-PK INHIBITION ACTIVITY AND USE THEREOF | 보령제약 주식회사 | 2022-08-25 | — | — | WO | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | PRKDC 316/4885TTK 1365/4885KCNH2 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.